National Biological Sample and Data Repository for Pulmonary Arterial Hypertension

The assembled collection of biospecimens and the associated clinical/genetic data will be the foundation for experiments with the statistical power to provide the insights from the state of the art technologies in genomics and proteomics. If the collection doesn’t exist, the insights available from the new technologies cannot find their way to PAH research. While generating a biobank is not a new idea, what is new is the inventory and tracking system, the software, specimen extraction, and communication with users to implement the Best Practices applied to PAH. The biobank will be the most economically efficient and have the greatest novelty and impact upon understanding PAH pathophysiology through the GWAS, NextGen sequencing, epigenomics, and proteomic approaches.

Study phase: Other

Study phase (if other): biorepository

Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.

Adults meeting the criteria of the diagnosis of WHO Group 1 PAH. These criteria are:
• mean pulmonary artery pressure (PAP) >25 mm Hg at rest (30 mm Hg with exercise),
• pulmonary capillary wedge pressure (PCWP) ?18 mm Hg (traditional is PWCP ?15 mm Hg)
• pulmonary vascular resistance (PVR) ?240 dynes·sec·cm-5.

Primary disease category: Asthma & Lung

Secondary disease categories: Heart/Cardiovascular

Sponsor: NHLBI

Projected enrollment dates: November 2015 to November 2016

Official study title: National Biological Sample and Data Repository for Pulmonary Arterial Hypertension